Gene · 6554
Papers3,134
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
81 to 100 of 3,134
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Implications of seven NTCP mutations for receptor stability and Hepatitis B Virus infectivity: A computational analysis. | Mutat Res | 2025 | 41290509 | PubTator, text mining | PubMed |
| Bulevirtide Monotherapy or in Combination for Chronic Hepatitis Delta: 2025 Update. | J Viral Hepat | 2025 | 41287135 | PubTator, text mining | PubMed |
| Protective Role of the Sodium Taurocholate Cotransporting Polypeptide S267F Variant Against Hepatitis B Virus Infection and Cirrhosis in the Vietnamese Population. | J Med Virol | 2025 | 41147800 | PubTator, text mining | PubMed |
| NTCP ubiquitination enables HBV infection. | JHEP Rep | 2025 | 41127880 | PubTator, text mining | PubMed |
| Amino acid substitutions at rheostat positions in the Na+/taurocholate cotransporting polypeptide substrate channel have pleiotropic effects. | Protein Sci | 2025 | 41088770 | PubTator, text mining | PubMed |
| Genomic medicine in hepatology: mechanisms and liver treatment strategies. | Mol Med | 2025 | 41023586 | PubTator, text mining | PubMed |
| Potential for Core Fucose-Targeted Therapy Against HBV Infection of Human Normal Hepatocytes. | Viruses | 2025 | 41012670 | PubTator, text mining | PubMed |
| Comment on Rinaldi et al. Assessment of Response and Safety of Bulevirtide Treatment in Patients with Chronic Delta Virus Infection: The ARISTOTLE Pilot Observational Study. Viruses 2025, 17, 251. | Viruses | 2025 | 41012655 | PubTator, text mining | PubMed |
| Epitranscriptomic Regulation of Hepatitis B Virus by RNA 5-Methylcytosine: Functions, Mechanisms, and Therapeutic Potential. | Viruses | 2025 | 41012587 | PubTator, text mining | PubMed |
| Episomal and integrated hepatitis B transcriptome mapping uncovers heterogeneity with the potential for drug-resistance. | Nat Commun | 2025 | 41006278 | PubTator, text mining | PubMed |
| Carrier cross-reactivities of the bile acid reabsorption inhibitors elobixibat, linerixibat, maralixibat, and odevixibat. | J Lipid Res | 2025 | 40998033 | PubTator, text mining | PubMed |
| An open-source multi-semantic annotation dataset and automated recognition tool for viral carcinogenesis factors. | Database (Oxford) | 2025 | 40996719 | PubTator, text mining | PubMed |
| Association of rs4646287 Polymorphism with the Risk of Hepatitis B Virus Infection and the Progression of Hepatocellular Carcinoma in an Iranian Population. | Iran Biomed J | 2025 | 40975795 | PubTator, text mining | PubMed |
| CDC42 supports HBV entry by NTCP translocation to the plasma membrane and macropinocytosis. | EMBO Rep | 2025 | 40954218 | PubTator, text mining | PubMed |
| Transcriptomic and Proteomics Analysis of a Lipid-Loaded HepaRG Model for Steatosis Reveals Altered Regulation in Lipid and Xenobiotic Metabolism. | Curr Drug Metab | 2025 | 40947715 | PubTator, text mining | PubMed |
| Interaction between W41 of the hepatitis B virus preS1 surface peptide and Y146/F274 of the cellular receptor molecule Na+/taurocholate co-transporting polypeptide is essential for virus entry. | Mol Pharmacol | 2025 | 40925208 | PubTator, text mining | PubMed |
| A novel synthetic bile acid derivative inhibits hepatitis B virus infection at entry step by interfering with the oligomerization of sodium taurocholate co-transporting polypeptide. | Antiviral Res | 2025 | 40889532 | PubTator, text mining | PubMed |
| Author Correction: Discovery of novel HBV core protein inhibitors by high throughput virtual screening. | Sci Rep | 2025 | 40877419 | PubTator, text mining | PubMed |
| VVX001 Induces preS-Specific Antibodies Reacting to Common HBV Genotypes in Hepatitis B Virus (HBV) Carrier Mice. | Vaccines (Basel) | 2025 | 40872938 | PubTator, text mining | PubMed |
| The Evolution of Cell Culture Systems to Study Hepatitis B Virus Pathogenesis and Antiviral Susceptibility. | Viruses | 2025 | 40872772 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6554/papers?page=5